CWP
NEUP

Cyndeo Wealth Partners’s Neuphoria Therapeutics NEUP Stock Holding History

Cyndeo Wealth Partners’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$71K – 500
2025
Q2 		$71K Hold
10,000
– – ﹤0.01% 460
2025
Q1 		$57.6K Buy
+10,000
New +$46.8K ﹤0.01% 443

Other funds holding NEUP

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PWM
Prosperity Wealth Management San Ramon, California $300M AUM 28.11% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cyndeo Wealth Partners's NEUP Position: Q3 2025 in Review

Cyndeo Wealth Partners sold out of Neuphoria Therapeutics (NEUP) in Q3 2025, closing a stake of 10,000 shares — an estimated $71K sold.

Cyndeo Wealth Partners first reported a position in NEUP in Q1 2025 and held it in 2 quarters. The position peaked at $71K in Q2 2025. 15 funds tracked by Wall St. Rank hold NEUP as of Q3 2025.

  • Cyndeo Wealth Partners reported no remaining Neuphoria Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cyndeo Wealth Partners sold 10,000 Neuphoria Therapeutics shares in Q3 2025, an estimated $71K.
  • Cyndeo Wealth Partners first reported a position in Neuphoria Therapeutics in Q1 2025 and held it in 2 quarters.
  • Cyndeo Wealth Partners's Neuphoria Therapeutics position peaked at $71K in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2025.

Based on Cyndeo Wealth Partners's 13F filing for Q3 2025, filed 10 Oct 2025.